Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis

Arivajiagane Arundhati1,4,*, Wen-Han Chuang1,*, Jen-Kun Chen2,*, Shin-E Wang3,*, Yi-Ming Shyr3, Jiun-Yu Chen2, Wei-Neng Liao2, Hsin-Wei Chen1, Yi-Min Teng1, Chiao-Chih Pai1 and Chih-Hong Wang1

1 Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan
2 Institute of Biomedical Engineering & Nanomedicine, National Health Research Institutes, Miaoli, Taiwan
3 Department of General Surgery, Taipei Veterans General Hospital, and National Yang Ming University, Taipei, Taiwan
4 Institute of Molecular Medicine and Bioengineering, National Chiao Tung University, Hsinchu, Taiwan

* These authors have contributed equally to this work

Published: January 11, 2019

Copyright: Arundhati et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to an error in proofreading, the total ERK, AKT, and S6K in Figure 4A are incorrect. The proper Figure 4A is shown below. In addition, updates have been made to the 3rd affiliation and a 4th affiliation has been added. Both are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

3 Department of General Surgery, Taipei Veterans General Hospital, and National Yang Ming University, Taipei, Taiwan
4 Institute of Molecular Medicine and Bioengineering, National Chiao Tung University, Hsinchu, Taiwan

Figure 4: Role of PRR in MAPK and PI3K/Akt pathways. Western results have shown in A. overexpression of human PRR in Panc-1 cells.

Original article: Oncotarget. 2016; 7:55437-55448. https://doi.org/10.18632/oncotarget.10583